Global and United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Report & Forecast 2022-2028

Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.
Market Analysis and Insights: Global and United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market
This report focuses on global and United States Non-Alcoholic Steatohepatitis (NASH) Drugs market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Non-Alcoholic Steatohepatitis (NASH) Drugs market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, by Type, Vitamin E & Pioglitazone accounting for % of the Non-Alcoholic Steatohepatitis (NASH) Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Hospital Pharmacy was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
This market is boosted by the growing prevalence of diabetes and obesity, and high investments for research and development, which leads to rising demand for NASH and others nonalcoholic fatty liver diseases (NAFLD) therapies in the market. As per the regional analysis, the well-established healthcare infrastructure with the high adoption rate of new technologies and increasing research activities, makes North America dominate this market.
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Scope and Market Size
Non-Alcoholic Steatohepatitis (NASH) Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Non-Alcoholic Steatohepatitis (NASH) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Non-Alcoholic Steatohepatitis (NASH) Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Vitamin E & Pioglitazone
Obeticholic Acid (OCA)
Elafibranor
Selonsertib & Cenicriviroc
Segment by Application
Hospital Pharmacy
Online Provider
Retail Pharmacy
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
AstraZeneca
Conatus Pharmaceuticals
Enzo Biochem
Galmed Pharmaceuticals
Genfit
Gilead
Horizon Pharma
Immuron
Intercept Pharmaceuticals
Novo Nordisk